AbbVie to acquire Nimble Therapeutics for $200m
The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.
AbbVie Continues Deal-Making Spree With $200M Nimble Buy
The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and cement its long-term growth prospects following the Phase II failure of emraclidine in schizophrenia and in anticipation of market erosion for Skyrizi and Rinvoq,
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.
AbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still Bearish
Shares of AbbVie Inc. oscillated between gains and losses Friday as the company’s latest acquisition drew mixed reactions from investors. AbbVie announced a $200 million deal to acquire Nimble Therapeutics,
AbbVie buys Roche spinout Nimble Therapeutics for $200M
AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble Therapeutics,
AbbVie To Acquire Nimble Therapeutics For $200 Mln In Cash
Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.
AbbVie Acquires Nimble Therapeutics in $200 Million Deal to Strengthen Immunology Pipeline
AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for psor
AbbVie Buying Nimble Therapeutics for $200M to Boost Immunology Pipeline
AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio. AbbVie on Friday said the deal adds Nimble's lead asset,
pharmaphorum17h
AbbVie adds psoriasis med with Nimble takeover
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...
BioPharma Dive3d
AbbVie to acquire Roche spinout Nimble in immune drug deal
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...
Crain's Chicago Business3d
AbbVie to acquire Wisconsin biopharma for $200 million
Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...
Business Insider3d
AbbVie to acquire Nimble Therapeutics for $200M cash at closing
AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in ...